Figure 2.

Effect of sodium glucose co-transporter-2 inhibition on kidney disease progression by presumed primary kidney disease (chronic kidney disease trials only)

Effects in IgA nephropathy, focal segmental glomerulosclerosis, and other glomerular diseases considered separately are provided in the appendix (p 18). Rate values are not presented for the combined subtotal and total populations due to the heterogeneity in rates across the individual trials. eGFR=estimated glomerular filtration rate. RR=relative risk. SGLT2i=sodium glucose co-transporter-2 inhibitor. *RR in the diabetic kidney disease or nephropathy subgroup excluding SCORED (which did not formally assess primary kidney disease) is 0·59 (95% CI 0·52–0·68).